Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 11, 2022

Risks and Benefits of SGLT2 Inhibitors in Type 2 Diabetes

Diabetologia

 

Additional Info

Diabetologia
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
Diabetologia 2022 Dec 01;65(12)2000-2010, E Marilly, J Cottin, N Cabrera, C Cornu, R Boussageon, P Moulin, JC Lega, F Gueyffier, M Cucherat, G Grenet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading